Resistance to first- and second-line antituberculosis drugs in Southern Taiwan: Implications for empirical treatment.
Journal of Microbiology, Immunology and Infection(2018)
摘要
We observed almost no resistance to the tested second-line antituberculosis drugs among non-MDR-Mtbs. Anti-tuberculosis regimen with pyrazinamide, ethambutol, fluoroquinolone, kanamycin, cycloserine and p-aminosalicylic acid can be empirically used for newly diagnosed MDR-TB cases. For previously treated MDR-TB patients, empirical ethambutol, pyrazinamide, ofloxacin, or moxifloxacin may not provide effective treatment because the resistance rates to these drugs were all >50%.
更多查看译文
关键词
Multidrug resistant tuberculosis,Extensively drug-resistant tuberculosis,Empirical treatment,Epidemiology,Taiwan
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络